[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Parnassia Groep\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100571894","dsm-5-personality-disorders-in-adults-with-autism-100571894",false,"NCT06726187","DSM-5 Personality Disorders in Adults With Autism","Inclusion criteria Inclusion criteria for ASD participants: (1) primary diagnosis of ASD according to the DSM-5-TR, (2) age 18+ years, (3) no intellectual disability, and (4) at least having completed a primary and secondary education.\n\nInclusion criteria for informants:\n\nParticipants were asked to identify individuals who knew them well and were capable of providing accurate descriptions of their personality traits, preferably informants that cohabited with the participants. When cohabitants were unavailable, participants were asked to identify \"the person who knows you best.\" Additionally, eligibility of informants for inclusion required that, historically, the informant and the participant talked at least monthly and interacted face-to-face at least yearly.\n\nExclusion criteria Exclusion criteria for ASD participants: (1) no ASD diagnosis, (2) current substance abuse, (3) psychotic disorders, (4) schizophrenia, (5) eating disorder, (6), mental retardation (IQ\\\u003C80), (7) suicidal ideations and (8) age \\\u003C18 years.\n\nExclusion criteria for informants: (1) age \\\u003C18 years, (2) intellectual disability, and (3) not being able to state and\u002For recognize psychological and problematic functioning of their participating relative with ASD.","ALL","18 Years",{"count":18,"type":19},102,"ESTIMATED","1 Day","OBSERVATIONAL","Rationale: Self-report measures are frequently used for research and clinical assessments of adults with autism spectrum disorder (ASD). However, there has been little research examining agreement between self-report and informant-report in this population. Reliable self-report measures are essential for conducting research with and providing high quality clinical services for adults with autism spectrum disorder.\n\nObjective: This study aims to examine the usefulness of self-report of DSM-5-TR PD traits in adults with ASD compared to informant-reports by administering the self-report screening measure of the Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).",[24],"Autism Spectrum Disorder",[26,27],"Autism","Personality disorder","RECRUITING","2026-07-15",{"date":31,"type":32},"2026-07-17","ACTUAL",{"date":34,"type":32},"2024-03-01",{"date":36,"type":19},"2027-01-29",{"name":38,"class":39},"Parnassia Groep","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100489695","clinical-study-evaluating-pharmacogenomics-informed-pharmacotherapy-versus-dosing-as-usual-in-psychiatric-disorders-100489695","NCT05656469","Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders","A New Intervention for Implementation of Pharmacogenetics in Psychiatry","PSY-PGx","Inclusion Criteria:\n\n1. Suffer from a depressive episode (major depressive disorder and bipolar disorder (currently depressive episode)) (as assessed by the MINI International Neuropsychiatric Interview (M.I.N.I.) in agreement with Diagnostic and Statistical Manual (DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Depression Scale (SIGH-D) with a score of 14 or higher) and\u002For suffer from an anxiety disorder (panic disorder, generalised anxiety disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH- A) with a score of 18 or higher) and\u002For suffer from a psychotic disorder (schizophrenia and schizoaffective disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Positive and Negative Symptom Scale (PANSS) with a score of 75 or higher).\n2. Have had an inadequate response to at least 1 psychotropic treatment during their life-time. Inadequate response is defined as insufficient efficacy of a psychotropic treatment when dosed high enough and maintained long enough, or discontinuation of a psychotropic treatment due to AEs or intolerability.\n3. Are about to switch (or have switched within the last 2 weeks prior to first contact with an investigator) to sertraline or escitalopram (for patients with mood or anxiety disorders), or to aripiprazole or risperidone (for patients with psychotic disorders) due to an inadequate response to or intolerance of the current\u002F previous medication.\n4. Currently receiving inpatient or outpatient psychiatric treatment.\n5. Be able to understand the requirements of the study and provide written informed consent to participate in this study; a signed and dated informed consent form (ICF) will be obtained from each patient before participation in the study.\n6. To give written consent to the use and disclosure of clinical data from their medical records for the purpose of this study.\n7. Age between ≥16 and \\\u003C70 years.\n8. Ownership of a mobile phone (Android or iOS operation system) for passive monitoring.\n\nExclusion Criteria:\n\n1. Patients with a history of prior pharmacogenomic testing\n2. Patients with no prior use of psychotropic medication (medication-naïve patients)\n3. Severe somatic comorbidities as reported in the subject's medical history or based on clinical chemistry\u002Felectrocardiography (ECG) results up to six months ago. If any of these comorbidities is detected on the basis of physical examination and\u002For clinical chemistry and\u002For ECG at the screening visit, participation is not possible.\n\n   * Liver disease defined as follows: Alanine-Aminotransferase (ALAT) \\>70u\u002FL\n   * Renal disease: Estimated glomerular filtration rate (eGFR) \\\u003C 60ml\u002Fmin\u002F1.73m2\n   * Diabetes: Blood glucose \\> 11.1 mmol\u002FL or twice a fasting glucose \\> 7.0 mmol\u002FL\n   * Cardiac disease: prolonged QT-interval.\n4. Alcohol and\u002For substance abuse and\u002For dependence (except nicotine)\n5. Polypharmacy defined as the routine use of five or more medications including over- the-counter, prescription and\u002For traditional and complementary medicines used by a patient (WHO 2019).\n6. Inability to use the mobile phone application\n7. Pregnant or breastfeeding women","16 Years","70 Years",{"count":52,"type":19},2500,"INTERVENTIONAL",[55],"NA","A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.",[58,59,60],"Mood Disorders","Anxiety Disorders","Psychotic Disorders",[62],"Pharmacogenetics","2026-05-29",{"date":65,"type":32},"2026-06-02",{"date":67,"type":32},"2023-02-23",{"date":69,"type":19},"2026-09",{"name":38,"class":39},9,""]